Work

Antiretroviral Activity, Pharmacokinetics, and Tolerability of MK-0518, a Novel Inhibitor of HIV-1 Integrase, Dosed As Monotherapy for 10 Days in Treatment-Naive HIV-1-Infected Individuals

Year: 2006

Type: article

Study designs: Randomized Controlled Trial, Clinical Trial

Source: JAIDS Journal of Acquired Immune Deficiency Syndromes

DOI: 10.1097/qai.0b013e31802b4956

Authors: Martin Markowitz, Javier O Morales-Ramirez, Bach-Yen Nguyen, Colin M Kovacs, Roy T Steigbigel, David A Cooper, Ralph Liporace, Robert Schwartz, Robin Isaacs, Lucinda R Gilde, Larissa Wenning, Jing Zhao, Hedy Teppler

Institutions: Aaron Diamond AIDS Research Center, Rockefeller University, Clinical Research Puerto Rico, Merck & Co., Inc., Rahway, NJ, USA (United States), Stony Brook University, UNSW Sydney, Albany Medical College

Language: English

Topic: HIV/AIDS drug development and treatment

Subfield: Infectious Diseases

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2053125329

FWCI: 31.55

Cites: 12

Cited by: 374

Related to: 10